Page 38 - GTM-3-1

Global Translational Medicine Immune response in humans due to COVID-19 infection

U S A. 2021;118(24):e2101161118. doi: 10.1007/s00011-022-01555-5
doi: 10.1073/pnas.2101161118 22. Lee KS, Wong TY, Russ BP, et al. SARS-CoV-2 Delta variant
induces enhanced pathology and inflammatory responses in
11. Schoggins JW, Rice CM. Interferon-stimulated genes K18-hACE2 mice. PLoS one. 2022;17(8):e0273430.
and their antiviral effector functions. Curr Opin Virol.
2011;1(6):519-525. doi: 10.1371/journal.pone.0273430
doi: 10.1016/j.coviro.2011.10.008 23. McCallum M, De Marco A, Lempp FA, et al. N-terminal
domain antigenic mapping reveals a site of vulnerability for
12. Murira A, Lamarre A. Type-I interferon responses: From SARS-CoV-2. Cell. 2021;184(9):2332-2347.e16.
friend to foe in the battle against chronic viral infection.
Front Immunol. 2016;7:609. doi: 10.1016/j.cell.2021.03.028
doi: 10.3389/fimmu.2016.00609 24. Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity
of SARS-CoV-2 variant Delta to antibody neutralization.
13. Supasa P, Zhou D, Dejnirattisai W, et al. Reduced Nature. 2021;596(7871):276-280.
neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent
and vaccine sera. Cell. 2021;184(8):2201-2211.e7. doi: 10.1038/s41586-021-03777-9
doi: 10.1016/j.cell.2021.02.033 25. Zheng Y, Zhuang MW, Han L, et al. Severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) membrane (M)
14. Torbati E, Krause KL, Ussher JE. The immune response protein inhibits type I and III interferon production by
to SARS-CoV-2 and variants of concern. Viruses. targeting RIG-I/MDA-5 signaling. Signal Transduct Target
2021;13(10):1911. Ther. 2020;5(1):299.
doi: 10.3390/v13101911 doi: 10.1038/s41392-020-00438-7
15. Low ZY, Yip AJW, Sharma A, Lal SK. SARS coronavirus outbreaks 26. Blanco-Melo D, Nilsson-Payant BE, Liu WC, et al.
past and present-a comparative analysis of SARS-CoV-2 and its Imbalanced host response to SARS-CoV-2 drives
predecessors. Virus Genes. 2021;57(4):307-317. development of COVID-19. Cell. 2020;181(5):1036-1045.e9.
doi: 10.1007/s11262-021-01846-9 doi: 10.1016/j.cell.2020.04.026
16. Kim JE, Heo JH, Kim HO, et al. Neurological complications 27. Hong MZ, Qiu R, Chen W, et al. Different clinical features of
during treatment of Middle East respiratory syndrome. children and adults in regional outbreak of Delta COVID-19.
J Clin Neurol. 2017;13(3):227-233. BMC Infect Dis. 2022;22(1):728.
doi: 10.3988/jcn.2017.13.3.227 doi: 10.1186/s12879-022-07707-6
17. Diao B, Wang C, Tan Y, et al. Reduction and functional 28. Zanza C, Romenskaya T, Manetti AC, et al. Cytokine storm
exhaustion of T cells in patients with coronavirus disease in COVID-19: Immunopathogenesis and therapy. Medicina
2019 (COVID-19). Front Immunol. 2020;11:827. (Kaunas). 2022;58(2):144.
doi: 10.3389/fimmu.2020.00827 doi: 10.3390/medicina58020144
18. Kaneko N, Kuo HH, Boucau J, et al. Loss of Bcl-6-expressing 29. Gil-Etayo FJ, Suàrez-Fernández P, Cabrera-Marante O,
T follicular helper cells and germinal centers in COVID-19. et al. T-helper cell subset response is a determining factor
Cell. 2020;183(1):143-157.e13. in COVID-19 progression. Front Cell Infect Microbiol.
doi: 10.1016/j.cell.2020.08.025 2021;11:624483.
19. Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. doi: 10.3389/fcimb.2021.624483
Omicron and Delta variant of SARS‐CoV‐2: A comparative 30. Neidleman J, Luo X, Frouard J, et al. SARS-CoV-2-specific
computational study of spike protein. J Med Virol. T cells exhibit phenotypic features of helper function, lack
2022;94(4):1641-1649. of terminal differentiation, and high proliferation potential.
doi: 10.1002/jmv.27526 Cell Rep Med. 2020;1(6):100081.
20. Bian L, Gao Q, Gao F, et al. Impact of the Delta variant on doi: 10.1016/j.xcrm.2020.100081
vaccine efficacy and response strategies. Expert Rev Vaccines. 31. Roncati L, Nasillo V, Lusenti B, Riva G. Signals of T 2
h
2021;20(10):1201-1209. immune response from COVID-19 patients requiring
doi: 10.1080/14760584.2021.1976153 intensive care. Ann Hematol. 2020;99(6):1419-1420.
21. Biswas B, Chattopadhyay S, Hazra S, Hansda AK, doi: 10.1007/s00277-020-04066-7
Goswami R. COVID-19 pandemic: The delta variant, T-cell 32. Elbadawy HM, Khattab A, El‐Agamy DS, et al. IL‐6 at
responses, and the efficacy of developing vaccines. Inflamm the center of cytokine storm: Circulating inflammation
Res. 2022;71(4):377-396. mediators as biomarkers in hospitalized COVID‐19 patients.

Volume 3 Issue 1 (2024) 8 https://doi.org/10.36922/gtm.2228